VPH2

Heart failure accounts for almost a quarter of all admissions to hospital for cardiovascular events, has a high mortality (median survival around 18 months), and places a great burden on all healthcare systems, with estimated direct costs of £905m (1350m) in the United Kingdom in 2000, 2% of total NHS expenditure.

Virtual pathological heart of the virtual physiological human (VPH2) project aims to develop a patient-specific computational modelling and simulation of the human heart to assist the cardiologist and the cardiac surgeon in defining the severity and extent of disease in patients with post-ischemic Left Ventricular Dysfunction (LVD), with or without ischemic mitral regurgitation (IMR). Specific computational methods will allow clinical decision making and planning of the optimal treatment for left ventricle-valve repair. The goal is not only to deploy a fully validated technology to partner clinical institutions, but also to develop a sustainable business model associated to it.

The associated technological aim of the project is to deliver the most advanced software application framework for the development of computer-aided medicine in cardiology and cardiac surgery available in the world, going beyond the state of the art of available models.

This goal will be achieved by integrating some of the leading Open Source software in the area of computer-aided medicine and of computational bioengineering. This framework will be used by VPH2 to realise its objectives, but also by any other future project (academic or industrial) aiming to improve or extend VPH2 objectives.

For further information, please visit:
http://www.vph2.eu

Project co-ordinator:
GMD - Gesellschaft für Medizinische Datenverarbeitung mbH

Partners:

  • Intercon Sp. Z o.o. (Poland)
  • Euro PMS ltd (United Kingdom)
  • Sorin Biomedica Cardio S.r.l. (Italy)
  • SCS S.r.l. (Italy)
  • EREYNITIKO AKADIMAIKO INSTITOUTO TECHNOLOGIAS YPOLOGISTON (Greece)
  • Westfälische Wilhelms-Universität Münster (Germany)
  • PATMOS S.r.l. (Italy)
  • Aminio AB (Sweden)
  • Ecole Polytechnique Fédérale de Lausanne (Switzerland)
  • University of Bedfordshire (United Kingdom)
  • Regione Lombardia (Italy)
  • Quality & Reliability S.A (Greece)

Timetable: from 07/2008 - to 06/2011

Total cost: € 5.180.000

EC funding: € 3.780.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

AI can Strengthen Pandemic Preparedness

How to identify the next dangerous virus before it spreads among people is the central question in a new Comment in The Lancet Infectious Diseases. In it, researchers discuss how...

'Future-Guided' AI Improves Se…

In the world around us, many things exist in the context of time: a bird’s path through the sky is understood as different positions over a period of time, and...

Study Finds One-Year Change on CT Scans …

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease...

New AI Tool Scans Social Media for Hidde…

A new artificial intelligence tool can scan social media data to discover adverse events associated with consumer health products, according to a study published September 30th in the open-access journal...

New AI Tools Help Scientists Track How D…

Artificial intelligence (AI) can solve problems at remarkable speed, but it’s the people developing the algorithms who are truly driving discovery. At The University of Texas at Arlington, data scientists...

Yousif's Story with Sectra and The …

Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which...

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

New Antibiotic Targets IBD - and AI Pred…

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases...

Highland to Help Companies Seize 'N…

Health tech growth partner Highland has today revealed its new identity - reflecting a sharper focus as it helps health tech companies to find market opportunities, convince target audiences, and...